Abstract | BACKGROUND: METHODS: This article offers a narrative review of bone-seeking radionuclides, examines the evidence of safety and efficacy for the treatment of painful skeletal metastases, and presents guidelines for their appropriate use in this patient population. RESULTS: Seven bone-seeking radionuclides have shown evidence of both safety and efficacy in reducing pain from diffuse skeletal metastases. 153Sm-EDTMP and 89Sr are most commonly used in the United States and have been safely utilized for both repeat dosing as well as concurrent dosing with cytotoxic chemotherapy. CONCLUSIONS: Targeted bone-seeking radionuclides are underutilized in the treatment of painful diffuse osteoblastic metastases. Several new agents are in active clinical investigation, and the pending approval of the first alpha-emitting radionuclide (223Ra) may offer a new class of agents that provide greater efficacy and less toxicity than those currently available for routine clinical use.
|
Authors | M Tomblyn |
Journal | Cancer control : journal of the Moffitt Cancer Center
(Cancer Control)
Vol. 19
Issue 2
Pg. 137-44
(Apr 2012)
ISSN: 1526-2359 [Electronic] United States |
PMID | 22487976
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Bone Neoplasms
(diagnosis, metabolism, radiotherapy, secondary)
- Humans
- Pain
(drug therapy, etiology, radiotherapy)
- Palliative Care
(methods)
- Radioisotopes
(pharmacokinetics, therapeutic use)
- Treatment Outcome
|